Christopher Linington

Christopher Linington

Auto-generated profile, based on publicly available information

Christopher Linington

University of Glasgow

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2006 in Brain
Verified
Journal Article
Open access
PDF file
RGRalf Gold
Ralf Gold
CLChristopher Linington
Christopher Linington
HLHans Lassmann
Hans Lassmann
In view of disease heterogeneity of multiple sclerosis and limited access to ex vivo specimens, different approaches must be undertaken to better understand disease pathogenesis and new therapeutic challenges. Here, we critically discuss models of experimental autoimmune encephalomyelitis (EAE) that reproduce specific features of the histopathology and neurobiology of multiple sclerosis and their shortcomings as tools to investigate emerging therapeutic approaches. By using EAE models we have understood mechanisms of T-cell mediated immune damage of the CNS, and the associated effector cascade of innate immunity. Also, the importance of humoral components of the immune system for demyelination has been delineated in EAE, before it was applied therapeutically to subtypes of multiple sclerosis. Yet, similar to multiple sclerosis, EAE is also heterogeneous and influenced by the selected autoantigen, species and the genetic background. In particular, the relevance of cytotoxic CD8 T cells for human multiple sclerosis has been underestimated in most EAE models, and no EAE model exists that mimics primary progressive disease courses of multiple sclerosis. Seventy years after the first description of EAE and the publication of >7000 articles, we are aware of the obvious limitations of EAE as a model of multiple sclerosis, but feel strongly that when used appropriately it will continue to provide a crucial tool for improving our understanding and treatment of this devastating disease.

1 July 2000 in The American Journal of Pathology
Verified
Journal Article
Closed access
BKBarbara Kornek
Barbara Kornek
MSMaria K. Storch
Maria K. Storch
Robert WeissertRobert Weissert
Robert Weissert
EWErik Wallstroem
Erik Wallstroem
ASAndreas Stefferl
Andreas Stefferl
HLHans Lassmann
Hans Lassmann

5 May 2003 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
EBEstelle Bettelli
Estelle Bettelli
MPMaria Pagany
Maria Pagany
HWHoward L. Weiner
Howard L. Weiner
CLChristopher Linington
Christopher Linington
RSRaymond A. Sobel
Raymond A. Sobel
VKVijay K. Kuchroo
Vijay K. Kuchroo
Multiple sclerosis (MS) is considered to be an autoimmune disease of the central nervous system (CNS) that in many patients first presents clinically as optic neuritis. The relationship of optic neuritis to MS is not well understood. We have generated novel T cell receptor (TCR) transgenic mice specific for myelin oligodendrocyte glycoprotein (MOG). MOG-specific transgenic T cells are not deleted nor tolerized and are functionally competent. A large proportion (>30%) of MOG-specific TCR transgenic mice spontaneously develop isolated optic neuritis without any clinical nor histological evidence of experimental autoimmune encephalomyelitis (EAE). Optic neuritis without EAE could also be induced in these mice by sensitization with suboptimal doses of MOG. The predilection of these mice to develop optic neuritis is associated with higher expression of MOG in the optic nerve than in the spinal cord. These results demonstrate that clinical manifestations of CNS autoimmune disease will vary depending on the identity of the target autoantigen and that MOG-specific T cell responses are involved in the genesis of isolated optic neuritis.

1 October 1998 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
MSMaria K. Storch
Maria K. Storch
ASAndreas Stefferl
Andreas Stefferl
UBUschi Brehm
Uschi Brehm
Robert WeissertRobert Weissert
Robert Weissert
EWErik Wallström
Erik Wallström
HLHans Lassmann
Hans Lassmann

9 December 2013 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
NMNicolas Molnarfi
Nicolas Molnarfi
USUlf Schulze-Topphoff
Ulf Schulze-Topphoff
MWMartin S. Weber
Martin S. Weber
JPJuan C. Patarroyo
Juan C. Patarroyo
TPThomas Prod’homme
Thomas Prod’homme
SZScott S. Zamvil
Scott S. Zamvil
Whether B cells serve as antigen-presenting cells (APCs) for activation of pathogenic T cells in the multiple sclerosis model experimental autoimmune encephalomyelitis (EAE) is unclear. To evaluate their role as APCs, we engineered mice selectively deficient in MHC II on B cells (B–MHC II−/−), and to distinguish this function from antibody production, we created transgenic (Tg) mice that express the myelin oligodendrocyte glycoprotein (MOG)–specific B cell receptor (BCR; IgHMOG-mem) but cannot secrete antibodies. B–MHC II−/− mice were resistant to EAE induced by recombinant human MOG (rhMOG), a T cell– and B cell–dependent autoantigen, and exhibited diminished Th1 and Th17 responses, suggesting a role for B cell APC function. In comparison, selective B cell IL-6 deficiency reduced EAE susceptibility and Th17 responses alone. Administration of MOG-specific antibodies only partially restored EAE susceptibility in B–MHC II−/− mice. In the absence of antibodies, IgHMOG-mem mice, but not mice expressing a BCR of irrelevant specificity, were fully susceptible to acute rhMOG-induced EAE, also demonstrating the importance of BCR specificity. Spontaneous opticospinal EAE and meningeal follicle–like structures were observed in IgHMOG-mem mice crossed with MOG-specific TCR Tg mice. Thus, B cells provide a critical cellular function in pathogenesis of central nervous system autoimmunity independent of their humoral involvement, findings which may be relevant to B cell–targeted therapies.

10 September 2007 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
EMEmily K. Mathey
Emily K. Mathey
TDTobias Derfuss
Tobias Derfuss
MSMaria K. Storch
Maria K. Storch
KWKieran R. Williams
Kieran R. Williams
KHKimberly Hales
Kimberly Hales
CLChristopher Linington
Christopher Linington
Axonal injury is considered the major cause of disability in patients with multiple sclerosis (MS), but the underlying effector mechanisms are poorly understood. Starting with a proteomics-based approach, we identified neurofascin-specific autoantibodies in patients with MS. These autoantibodies recognize the native form of the extracellular domains of both neurofascin 186 (NF186), a neuronal protein concentrated in myelinated fibers at nodes of Ranvier, and NF155, the oligodendrocyte-specific isoform of neurofascin. Our in vitro studies with hippocampal slice cultures indicate that neurofascin antibodies inhibit axonal conduction in a complement-dependent manner. To evaluate whether circulating antineurofascin antibodies mediate a pathogenic effect in vivo, we cotransferred these antibodies with myelin oligodendrocyte glycoprotein–specific encephalitogenic T cells to mimic the inflammatory pathology of MS and breach the blood–brain barrier. In this animal model, antibodies to neurofascin selectively targeted nodes of Ranvier, resulting in deposition of complement, axonal injury, and disease exacerbation. Collectively, these results identify a novel mechanism of immune-mediated axonal injury that can contribute to axonal pathology in MS.